Fig. 7: SGI-1776 inhibits prostate cancer growth and osteolytic activity in vivo.

a The CCK-8 assay was used to test the relative viability of RM1 cells after 24 h treatment with SGI-1776 (1.1, 3.3 or 10 μM). b Schematic representation of the experiment. RM1 cells was injected into the tibiae of 7-week-old male mice. Starting 2 days later, the tibiae were injected with PBS, vehicle or either 10 mg/kg or 30 mg/kg body weight SGI-1776. c, d The tibiae were collected on day 9, sectioned and subjected to hematoxylin and eosin staining (c) or TRAP staining (d) with histomorphometry to determine the tumor area relative to total bone area and the No.OCs) (sham, n = 5; vehicle, n = 5; 10 mg/kg body weight SGI-1776, n = 5, 30 mg/kg body weight SGI-1776, n = 5). e, f The tibiae were collected on day 14 and subjected to µCT: representative µCT images (scale bars, 500 μm) (e); quantitative µCT analysis of tibial trabecular bone variables (sham, n = 6; vehicle, n = 9; 10 mg/kg body weight SGI-1776, n = 10; 30 mg/kg body weight SGI-1776, n = 10) (f). The results are presented as mean ± s.d. Statistical differences were analyzed by using one-way ANOVA with Tukey’s multiple comparisons test. ns, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.